- Sep 27, 2005
- 1,171
- 14
- 0
Drug companies are changing one molecule of a drug and reselling it under another name so they can have rights to it.
This is what happens when you deal within the US health care market. I just heard about this yesterday. I heard many times how the cost of drugs in the US is high because of research and development. They just won't give up their profits and will said anything to keep them. The fact that they hold people's lives in their hands does not matter. All that matters is if you can pay or not.
"Of $200 billion in yearly sales, the prescription drug industry spends only $5-6 billion (2.5-3%) on creating new drugs. That very limited expenditure on new drugs has produced very few drugs that can be called innovative or an improvement on older, less expensive, drugs. Compare that $5-6 billion figure with (1) the $3.8 billion spent yearly on direct to consumer (mostly TV) advertising or (2) the 35% of their revenues ($70 billion) spent on marketing and administration (data obtained by Dr. Angell from Securities and Exchange Commission (SEC) and shareholder reports for 2001)."
http://www.psc-cuny.org/drugprices.htm
This is what happens when you deal within the US health care market. I just heard about this yesterday. I heard many times how the cost of drugs in the US is high because of research and development. They just won't give up their profits and will said anything to keep them. The fact that they hold people's lives in their hands does not matter. All that matters is if you can pay or not.
"Of $200 billion in yearly sales, the prescription drug industry spends only $5-6 billion (2.5-3%) on creating new drugs. That very limited expenditure on new drugs has produced very few drugs that can be called innovative or an improvement on older, less expensive, drugs. Compare that $5-6 billion figure with (1) the $3.8 billion spent yearly on direct to consumer (mostly TV) advertising or (2) the 35% of their revenues ($70 billion) spent on marketing and administration (data obtained by Dr. Angell from Securities and Exchange Commission (SEC) and shareholder reports for 2001)."
http://www.psc-cuny.org/drugprices.htm

